升清降浊汤联合重组人血管内皮抑制素腹腔灌注对恶性腹水患者血管内皮生长因子的影响
|
摘要
[目的]观察升清降浊汤联合重组人血管内皮抑制素腹腔灌注治疗恶性腹水的疗效及对血管内皮因子(VEGF)的影响。[方法]82例恶性腹水患者随机分为观察组42例和对照组40例,对照组采用重组人血管内皮抑制素腹腔灌注,观察组在此基础上加用升清降浊汤口服,共治疗4周。观察2组患者临床疗效、中医症状改善情况、KPS评分及腹水VEGF表达水平。[结果]观察组在临床疗效方面优于对照组(P<0.05),同时观察组在改善中医症状、KPS评分方面也优于对照组(P<0.05),观察组腹水VEGF表达水平较对照组降低,差异有统计学意义(P<0.05)。[结论]升清降浊汤联合重组人血管内皮抑制素腹腔灌注治疗恶性腹水效果显著,并可能通过下调VEGF表达来抑制肿瘤血管生长,减少腹水生成。
[Objective]To observe the effect of Ascending Lucidity Descending Turbidity Decoction(ALDTD)combined with recombtnant human endostation on vascular endothelial growth factor(VEGF)of malignant ascites.[Methods]82 patients with malignant ascites were randomly divided into observation group(42 cases)and control group(40 cases).The control group was given Endostar intraperitoneal perfusion,and the observation group was given ALDTD and Endostar.The two groups were treated for 4 weeks.The clinical efficacy,improvement of TCM symptoms,KPS score and VEGF expression level of two groups were observed.[Results]The observation group was superior to the control group in clinical efficacy(P<0.05),and the observation group was superior to the control group in improving TCM symptoms and KPS scores(P<0.05).The expression of VEGF in ascites of the observation group was lower than control group(P<0.05).[Conclusion]ALDTD combined with Endostar intraperitoneal perfusion is effective in the treatment of malignant ascites,and may inhibit tumor angiogenesis and reduce ascites formation by down-regulating the expression of VEGF.
[Objective]To observe the effect of Ascending Lucidity Descending Turbidity Decoction(ALDTD)combined with recombtnant human endostation on vascular endothelial growth factor(VEGF)of malignant ascites.[Methods]82 patients with malignant ascites were randomly divided into observation group(42 cases)and control group(40 cases).The control group was given Endostar intraperitoneal perfusion,and the observation group was given ALDTD and Endostar.The two groups were treated for 4 weeks.The clinical efficacy,improvement of TCM symptoms,KPS score and VEGF expression level of two groups were observed.[Results]The observation group was superior to the control group in clinical efficacy(P<0.05),and the observation group was superior to the control group in improving TCM symptoms and KPS scores(P<0.05).The expression of VEGF in ascites of the observation group was lower than control group(P<0.05).[Conclusion]ALDTD combined with Endostar intraperitoneal perfusion is effective in the treatment of malignant ascites,and may inhibit tumor angiogenesis and reduce ascites formation by down-regulating the expression of VEGF.
引文
[1]秦叔逵,杨柳青,梁军,腔内应用重组人血管内皮抑制素和/或顺铂治疗恶性胸腹腔积液的前瞻性随机对照全国多中心Ⅲ期临床研究[J].临床肿瘤学杂志,2017,22(3):193-202.
[2]张菲菲,金世柱,刘自帅.恶性腹水的治疗新观点[J].胃肠病学和肝病学杂志,2017,26(4):476-478.
[3] Zhan N,Dong WG,Wang J.The clinical significance of vascular endothelial growth factor in malignant ascites[J].Tumor Biol,2016,37(3):3719-3725.
[4]黄毅超,刘云军,高颜凤,等.恩度胸腔灌注联合顺铂化疗治疗肺癌所致的恶性胸腹水患者血清因子含量及临床疗效分析[J].中南医学科学杂志,2018,46(2):180-182.
[5]加米兰·吴斯曼,沙吾丽·沙特江,贾存东.恩度联合香菇多糖在姑息性治疗癌性腹水的临床疗效[J].世界最新医学信息文摘,2017,17(37):103-104.
[6]韦婕,陈建,胡冰,等.不同剂量的重组人血管内皮抑素腹腔给药对腹水瘤小鼠的疗效观察[J].安徽医药,2018,22(3):414-418.
[7][清]黄元御.四圣心源[M].北京:人民军医出版社,2011:76-76.
[8]冯高飞,陈若,陈伟钊.升清降浊汤治疗原发性肝癌腹水的疗效观察[J].辽宁中医杂志,2015,42(7):1285-1286.
[9]石远凯,孙燕,于金明,等.中国晚期原发性肺癌诊治专家共识(2016年版)[J].中国肺癌杂志,2016,19(1):1-15.
[2]张菲菲,金世柱,刘自帅.恶性腹水的治疗新观点[J].胃肠病学和肝病学杂志,2017,26(4):476-478.
[3] Zhan N,Dong WG,Wang J.The clinical significance of vascular endothelial growth factor in malignant ascites[J].Tumor Biol,2016,37(3):3719-3725.
[4]黄毅超,刘云军,高颜凤,等.恩度胸腔灌注联合顺铂化疗治疗肺癌所致的恶性胸腹水患者血清因子含量及临床疗效分析[J].中南医学科学杂志,2018,46(2):180-182.
[5]加米兰·吴斯曼,沙吾丽·沙特江,贾存东.恩度联合香菇多糖在姑息性治疗癌性腹水的临床疗效[J].世界最新医学信息文摘,2017,17(37):103-104.
[6]韦婕,陈建,胡冰,等.不同剂量的重组人血管内皮抑素腹腔给药对腹水瘤小鼠的疗效观察[J].安徽医药,2018,22(3):414-418.
[7][清]黄元御.四圣心源[M].北京:人民军医出版社,2011:76-76.
[8]冯高飞,陈若,陈伟钊.升清降浊汤治疗原发性肝癌腹水的疗效观察[J].辽宁中医杂志,2015,42(7):1285-1286.
[9]石远凯,孙燕,于金明,等.中国晚期原发性肺癌诊治专家共识(2016年版)[J].中国肺癌杂志,2016,19(1):1-15.